The miR Sentinel™ Test is the only standalone, non-invasive liquid biopsy urine test that accurately detects, classifies and monitors prostate cancer at the molecular level with 95% Sensitivity and Specificity.Learn More
The miR Scientific Disease Management Platform™ is transforming cancer management by delivering actionable and accurate results to physicians and patients from a single urine sample, answering the three most important questions:
Is cancer present? How severe is it? What’s next?
Our technology identifies molecular evidence of malignancies from the entire prostate gland, even in early onset of the disease, so if the test shows that cancer is not present, patients and physicians can confidently conclude that no cancer is present at the time of diagnosis. No means No.
Depending on the risk tolerance of patients and physicians, they may decide on monitoring the disease for progression non-invasively under an active surveillance protocol or elect to undergo a definitive treatment.
An overwhelming majority of prostate cancer patients have an indolent, or clinically insignificant localized cancer that does not require a definitive treatment. For patients with low risk classifications, a physician may recommend a follow up under an active surveillance protocol, which for patients simply entails providing more urine samples periodically to ensure the disease has not progressed.
Patients whose molecular signature indicates the presence of high grade disease typically would undergo interventional definitive treatment, the specifics of which will be determined by the specialist care provider. Our technology identifies molecular evidence of the malignancies from the entire prostate gland, even in early onset of the disease. Yes means Yes and No means NO.
Accelerate the right diagnosis and treatment for individual cancer management with accurate diagnosis, classification, and monitoring.
Help patients avoid the invasive, inaccurate, and painful diagnostic procedures that are the current standard of care. miR delivers results with zero contact.
Broaden access to life-saving cancer screening with a completely standalone urine test that diagnoses and classifies prostate cancer with no additional testing requirements.
The miR Disease Management Platform™ is peer-reviewed and validated for the screening and classification of prostate cancer.
Rapid turnaround of reliable information guides treatment decisions and enables true cost-effectiveness in prostate cancer screening and management.
Unlike biopsies, MRIs, and other current options, the miR platform is high-throughput, easily administered, and cost-effective for large volumes of patients.
Prostate cancer is prevalent and deadly.
It represents the highest number of new cancer cases diagnosed annually and is the second leading cause of cancer deaths among men. Early detection and the ability to identify high grade disease early are key to effective disease management.
Unlike other cancers, most prostate cancers are indolent and are unlikely to ever need treatment, and only a relatively small number of prostate cancer patients have aggressive disease that requires intervention.
The current standard of care relies on PSA (Prostate Specific Antigen) and Digital Rectal Exams (DRE) to trigger core needle biopsies for the detection and diagnosis of prostate cancer.
It is inaccurate, invasive and often results in overtreatment. 70% of diagnostic core needle biopsies are unnecessary and consequently incur cost and morbidities.
The ineffectiveness of today’s standard of care leads many men to completely avoid the screening process. It is estimated that over 60% of age-eligible men remain unscreened.
Invasive, expensive and inaccurate with 44% Sensitivity
Primary Care Visit
Multiple Digital Rectal Exams
Multiple PSA Blood Tests
1 or More Prostate Biopsies
Easily Administered, Pain-Free, Accurate, Non-Invasive, with 95% Sensitivity and Specificity
1 Urine Sample
Our non-invasive, pain-free prostate cancer diagnostic testing and monitoring platform helps healthcare providers, patients, and employers realize true cost-effectiveness and efficiency in prostate cancer screening and management for the first time.
Leverage the most accurate prostate cancer decision-making platform to identify and rapidly treat patients with the greatest need.
Experience a non-invasive, accurate, accessible prostate cancer test that delivers clear results to you and your doctor with a single urine specimen.
Keep your employees and their families healthy and reduce excessive urologic cancer screening, treatment costs and unproductive workdays with a straightforward, validated and highly accessible urine test.
Our molecular diagnostic capabilities are a novel approach to cancer detection, classification, and monitoring, using advanced sncRNA interrogation techniques, a proprietary scoring algorithm and innovative clinical decision support tools.
miR’s technology isolates pre-classified, informative RNA entities from urinary exosomes, and uses proprietary tools to detect and process signals from numerous RNA entities that are evident in the specimens.
miR Scientific’s Sentinel™ test is healthcare’s first and only truly standalone urine test that diagnoses and classifies prostate cancers with 95% Sensitivity and Specificity—no rectal exam, blood test, biopsy nor strict urine requirements.
miR’s test provides the most comprehensive prostate cancer surveillance and clinical decision-making tool across the continuum of cancer care.